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Abstract
Post-transcriptional events in the life of an RNA including RNA processing, transport, translation
and metabolism are characterized by the regulated assembly of multiple ribonucleoprotein (RNP)
complexes. At each of these steps, there is the engagement and disengagement of RNA-binding
proteins until the RNA reaches its final destination. For retroviral genomic RNA, the final
destination is the capsid. Numerous studies have provided crucial information about these
processes and serve as the basis for studies on the intracellular fate of retroviral RNA. Retroviral
RNAs are like cellular mRNAs but their processing is more tightly regulated by multiple cis-acting
sequences and the activities of many trans-acting proteins. This review describes the viral and
cellular partners that retroviral RNA encounters during its maturation that begins in the nucleus,
focusing on important events including splicing, 3' end-processing, RNA trafficking from the nucleus
to the cytoplasm and finally, mechanisms that lead to its compartmentalization into progeny virions.
Background
The life of an mRNA is directed by the protein compo-
nents of ribonucleoprotein particles (RNP) whose roles
include nuclear processing reactions, transport, transla-
tion and degradation. Retroviral replication depends on
many of the same processes to form viral mRNA and
genomic RNA providing an experimentally tractable sys-
tem to study the cis and trans determinants of mRNA fate.
In this review, we summarize the current understanding of
the processes affecting retroviral RNA metabolism as the
RNA moves from its site of synthesis within the nucleus to
its encapsidation into viral particles that emerge from the
plasma membrane. The field has not only illuminated the
cellular processes regulating RNA fate in general but also
provided insights into potential strategies to impair repli-
cation of these viral pathogens.
Preserving genome-length RNA
Splicing control – the role of the NRS of ASV
The expression of viral proteins from unspliced, incom-
pletely spliced and fully spliced transcripts has necessi-
tated that retroviruses evolve strategies to control the
extent of RNA splicing. Extensive studies of avian sarcoma
virus (ASV) splicing revealed three mechanisms of splic-
ing control. The first involves the maintenance of subop-
timal 3' splice site (ss) signals. Use of the env  3'ss is
controlled by a suboptimal branchpoint (bpt) sequence
and a nearby exonic splicing enhancer (ESE) [1,2] whereas
the src 3' ss has a suboptimal pyrimidine tract (ppt) [3].
Mutations that improved the quality of the signals
increased splicing and had detrimental effects on replica-
tion. Consistent with a requirement of inefficient splicing
for optimal replication, revertants contained mutations
that restored inefficient splicing. In addition to subopti-
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mal splicing signals, a second, poorly characterized nega-
tive element is also present upstream of the src 3' ss [4,5].
Whether this element represents an intronic splicing
silencer (ISS) and what factors bind to it remains to be
determined. These two splicing control mechanisms are
shared with HIV (discussed below). A third, novel control
element in Rous sarcoma virus (RSV), that is apparently
unique to avian retroviruses, is the negative regulator of
splicing, or NRS [6,7]. The NRS is thought to represent an
elaborate pseudo-5'ss that non-productively interacts with
and sequesters the viral 3' splice sites such that productive
splicing with the authentic 5'ss cannot occur (Figure 1). In
addition to its established role in splicing control, the NRS
serves a second function in promoting efficient polyade-
nylation of viral transcripts, as discussed below.
The NRS was originally identified from gag intron dele-
tion mutations that increased splicing in RSV [6-8]. The
ability of the NRS to block splicing of heterologous
introns facilitated elucidation of factors that bind to it and
its mechanism of action [6]. Unlike other negative ele-
ments in HIV and RSV that are close to 3' splice sites, the
~230 nt NRS is located in the gag intron approximately
300 nt from the 5'ss and more than 4000 nt from the first
of two alternative 3' splice sites (env and src) [9]. Mutagen-
esis studies determined the NRS to be bipartite; splicing
inhibition requires a diffuse upstream purine-rich ele-
ment separated by ~115 nt from a discrete downstream
sequence that resembles a conventional but degenerate
U1-type 5' ss [9-12]. Overlapping the degenerate U1-type
5'ss is a consensus binding site for U11 snRNP, a factor
that serves an analogous role to U1 in binding the 5'ss of
a rare class of introns that are spliced by a second, low
abundance spliceosome [13]. Binding of both U1 and
U11 to the NRS has been demonstrated however it is the
interaction with U1 that leads to splicing inhibition
[10,11,14]. The mechanism by which U1 binding to the
NRS leads to inhibition rather than NRS splicing is not
clear, but may involve an aberrant U6 interaction at a later
step (M.T.M., unpublished). The U1/U11 sites overlap
and thus binding is mutually exclusive. U11 binding may
regulate splicing inhibition by modulating U1 binding,
and contribute to the balance of unspliced to spliced RNA
and replication. Thus, determining the cis and trans factors
that govern U1 and U11 binding was important.
The upstream, purine-rich region of the NRS was shown
to have potent splicing enhancer activity and to bind
members of the SR protein family of splicing factors and
hnRNP H [11,15,16]. One function of splicing enhancers
and SR proteins is recruitment of components of the splic-
ing apparatus. In the case of the NRS, it was shown that
the role of the enhancer region and SR proteins was to
recruit U1 to the downstream degenerate 5'ss. In contrast,
Model for NRS effects on splicing and polyadenylation Figure 1
Model for NRS effects on splicing and polyadenylation. Schematic of RSV RNA with exons depicted as boxes and 
introns shown as thin lines. The light shading represents the upstream SR protein binding region of the bipartite NRS, and the 
darker shading depicts the region that binds U1 snRNP. SR proteins promote U1 binding, which initiates early interactions with 
factors associated with the viral 3' splice site (env in this example), and this is thought to mature into a spliceosome-like NRS 
inhibitory complex (indicated by the large oval) that forms between the NRS and the viral 3' splice site but which is catalytically 
inactive (an X over the intron); a possible role for U6 snRNP is indicated by the question mark. The NRS complex sequesters 
the 3'ss from interacting with the authentic viral 5'ss to block splicing. The NRS complex may influence polyadenylation by 
serving to stabilize the binding of splicing factors to the weak viral 3' splice site, which can then either recruit or stabilize the 
polyadenylation complex (arrow) and thereby enhance polyadenylation of viral unspliced RNA. U11 snRNP modulates NRS 
function by antagonizing U1 binding and assembly of the NRS inhibitory complex. A downstream region (intermediate shading) 
binds hnRNP H, which recruits U11 to a site that overlaps the U1 binding site.  Retrovirology 2006, 3:18 http://www.retrovirology.com/content/3/1/18
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the SR protein-binding region was not necessary for effi-
cient U11 binding [11]. The NRS itself forms an early spli-
ceosome-like complex that is dependent on U1 and SR
proteins, and this complex can interact with a 3'ss in a U1-
dependent manner [17-19]. This interaction persists into
an ATP-dependent, more mature splicing-like complex,
however this complex is distinguished from authentic
splicing complexes in that the U4:U6/U5 tri-snRNP is not
stably bound and the U5-associated protein Prp8 cannot
be cross-linked to the 5' ss [198]. It is this aberrant snRNP
association that presumably accounts for assembly of a
non-catalytic complex that leads to sequestration of the
viral 3' ss and culminates in splicing inhibition.
The determinants for U11 binding are largely distinct
from U1. U11 is at a competitive disadvantage for NRS
binding, being 100-fold less abundant than U1 [20]. It
was recently shown that optimal U11 binding requires an
upstream 3'ss-like sequence and a downstream G-rich
region [21]. The downstream G-rich region binds hnRNP
H, and mutations in the G-tracks or depletion of hnRNP
H reduces U11 binding in vitro and in vivo [22]. These les-
sons from RSV suggested a more general role for hnRNP H
in U11 binding and splicing of authentic minor-class
introns. Indeed, the SCN4A and P120 minor-class introns
have G tracts, bind hnRNP H, and require hnRNP H for
optimal splicing [22]. HnRNP H also plays a role in U1
binding to an HIV-1 enhancer [23], which is consistent
with recent demonstrations that splicing of some U2-
dependent introns requires hnRNP H [24,25].
HIV-1 splicing
In contrast to murine leukemia and avian sarcoma viruses,
the increased coding capacity of HIV-1 has necessitated
the evolution of a more complex splicing regimen. In
addition to structural proteins, HIV-1 expresses six addi-
tional proteins that regulate various facets of the virus life-
cycle [26]. To account for this increased coding potential,
the 9 kb HIV-1 transcript is processed into over 30 mRNAs
through alternative splicing [27,28]. The products are
grouped into three size classes: the unspliced, 9 kb RNA
encoding Gag and Gag/Pol, the 4 kb, singly spliced RNAs
that encode Vif, Vpr, Vpu and Env, and the 2 kb, multiply
spliced RNAs that express Tat, Rev and Nef. Generation of
the required viral RNAs is achieved through the combina-
torial use of five 5' splice sites (SD1-5) and nine 3' splice
sites (ss) (SA1-3, SA4a,b,c, SA5-SA7). The production of a
spectrum of RNAs from unspliced to multiply spliced
necessitated the development of multiple mechanisms to
control the extent of viral RNA splicing since a substantial
amount of unspliced RNA is needed for replication. Initial
analysis of HIV-1 RNA processing focused on the splice
sites themselves and demonstrated that while the 5'ss
were highly active, the 3'ss were suboptimal due to altera-
tions in either the ppt or bpt sequences [29-31] (Figure 2).
Subsequent research determined that the suboptimal
nature of the 3'ss of HIV-1 was not the only point of regu-
lation. It was established that exon sequences also influ-
ence the use of individual 3'ss. These exon regulatory
sequences fall into two groups; exon splicing enhancers
(ESEs) that act to enhance recognition and use of the adja-
cent splice site, and exon splicing silencers (ESSs) that
suppress the use of adjacent 3'ss. To date, four ESSs have
been mapped and control the use of the 3'ss for Vpr (ESS-
V), Tat (ESS2, ESS2p), and the terminal 3'ss (ESS3)
[30,32-37]. For ESS-V, ESS2, and ESS3, function is
dependent upon an interaction with members of the
hnRNP A/B protein family [34,38-40] that results in an
early block to spliceosome formation. In the case of ESS3,
initial work suggested that binding of hnRNP A1 to ESS3
initiates oligomerization of hnRNP A1 along the RNA,
sterically hindering recognition of the ppt and bpt sites by
the corresponding splicing factors [41]. Subsequent anal-
yses suggested an alternative mechanism and the involve-
ment of an intronic splicing silencer (ISS) to which
hnRNP A1 also binds [42,43]. Multiple hnRNP A1 bind-
ing sites have also been mapped within ESS3 [42]. Muta-
tions that disrupt hnRNP A1 binding to either the ISS or
ESS3 result in partial alleviation of inhibition and muta-
tion of both is more severe [40], suggesting hnRNP A1
proteins, bound at ESS3 and ISS, might interact to loop
out the intervening sequence and impair splicing factor
binding to the bpt and ppt. Such a looping mechanism
involving hnRNP A1 binding to separate sites has been
proposed for regulation of exon 7B in the hnRNP A1 pre-
mRNA [44,45]. Function of ESS2p is less well studied but
correlates with hnRNP H binding [35].
Countering the inhibitory signals of the ESSs are the three
ESEs present within the first (ESE2, GAR) and second
(ESE3) coding exon of Tat [32,37,46-50]. Through inter-
action with one of several members of the SR protein fam-
ily, the ESEs act by facilitating the recruitment to and/or
stabilization of factors that bind the adjacent 3'ss [51-54].
Overexpression of SF2/ASF leads to enhanced use of SA2
and to a lesser extent SA1 [55,56], and increased expres-
sion of SC35 and SRp40 augment use of SA3, presumably
by blocking hnRNP A1 binding to the adjacent ESS2
[55,56]. A similar competition model was suggested to
explain the countering activities of ESE3 and ESS3 that
affect SA7 use [42,48,49]. In contrast to ESE2 and ESE3,
the enhancer downstream of SA5 (GAR) appears to be
more complicated. The 5' portion of this bipartite ESE
binds SF2/ASF and the 3' half interacts with SRp40 [46].
Point mutations within GAR that abrogate factor binding
to either domain reduce the efficiency of this element. In
addition to promoting SA5 use, this ESE also functions in
the recognition of the downstream 5'ss (SD4) by U1
snRNP. Inactivation of the GAR enhancer results in a dra-
matic increase in the ligation of SD1 to SA7, bypassing allRetrovirology 2006, 3:18 http://www.retrovirology.com/content/3/1/18
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Processing of HIV-1 RNA Figure 2
Processing of HIV-1 RNA. Outlined in the figure are the cis-acting components of the HIV-1 RNA which control its 
processing. Indicated are the positions of the 5' splice sites (arrows above the unspliced RNA), 3' splice sites (brackets below 
the unspliced RNA), and the various ESS and ESE elements that modulate splice site use. At top is an outline of viral genome 
and on the bottom, the exons which comprise the major spliced forms (4.0 kb singly spliced and 1.8 kb multiply spliced) of the 
genomic RNA are indicated by black boxes. Multiple spliced RNAs combining or excluding various exons encode each of the 
viral accessory proteins.Retrovirology 2006, 3:18 http://www.retrovirology.com/content/3/1/18
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of the splice acceptors used to produce the viral regulatory
protein mRNAs (SA3, SA4a-c, SA5) [46]. Therefore, this
GAR enhancer appears to play a critical role in ensuring
the correct processing of HIV-1 RNA. As one indication of
the delicate balance required to achieve the needed levels
of the various viral RNAs, a point mutation within env
results in generation of aberrant spliced products due to
the creation of a splicing enhancer that activates a cryptic
3'ss (SA6) [23,57].
Control of splicing in other retroviruses
While RNA processing has been most extensively studied
in ASV and HIV-1, work in other systems has also illumi-
nated patterns of splicing regulation. Studies of equine
infectious anemia virus (EIAV) have identified both cis
and trans modulators of RNA processing. Examination of
EIAV splice sites revealed that both the 5'ss and bpt
sequences do not deviate significantly from consensus. In
contrast, the polypyrimidine tracts are interrupted by
purines, which may reduce splice site usage by decreasing
binding of the splicing factor U2AF [58]. The purine-rich
element (PRE) that comprises the EIAV Rev (eRev) bind-
ing site is also involved in splicing regulation [59,60].
Deletion of the PRE results in a marked increase in
unspliced and Tat-encoding RNAs and a reduction in eRev
RNA [58]. This observation suggests that the PRE acts like
an ESE to promote adjacent splice site use. In vitro exper-
iments demonstrated that SF2/ASF can bind the PRE
[60,61]. However, overexpression of SF2/ASF failed to
promote use of the splice site adjacent to the PRE but
rather increased the level of unspliced viral RNA and
reduced the quantity of eRev RNA. In parallel experi-
ments, hnRNP A1 overexpression failed to alter viral RNA
splicing patterns [58].
In contrast to HIV-1, there is only a limited understanding
of splicing control in human T cell leukemia virus type 1
(HTLV-1). Like HIV-1, HTLV-1 produces several factors, in
addition to the structural proteins, by alternative splicing.
Little is known of the cis-acting elements controlling
splice site use but evidence of regulation is provided by
the marked differences in abundance of the various
spliced RNA isoforms in different infected cell lines
[62,63]. Overexpression of SF2/ASF or hnRNP A1 alters
HTLV-1 RNA splicing patterns [63] and loss of hnRNP A1
expression leads to an accumulation of unspliced viral
RNA and increased virus production [64]. Although the
effect of hnRNP A1 depletion could be attributed to
affects on splicing, the data could also be explained if
hnRNP A1 inhibits viral RNA transport to the cytoplasm
(putatively by inhibiting binding of the HTLV-1 Rev-like
factor, Rex, to the viral RNA) [65].
Several cis-acting elements that affect RNA stability and
processing in Moloney murine leukemia virus (MoMLV)
have also been identified. Analysis of sequences adjacent
to the 3'ss revealed several elements that control splicing
[66]. Deletion of exon sequences downstream of the 3'ss
resulted in a total loss of spliced viral RNA, suggesting that
the region may contain an ESE as seen for EIAV, HIV-1 and
ASV. In contrast, deletion of 140 nt immediately upstream
of the bpt sequence resulted in a marked elevation in the
spliced/unspliced viral RNA ratio, consistent with the
presence of a splicing silencer. However, the region sur-
rounding the 3'ss is not the only one that influences splic-
ing. Another element located within the CA region is
required for accumulation of spliced viral RNA [67,68].
This element contrasts with the NRS of ASV as the MoMLV
element would appear to be a stimulator of viral RNA
splicing. Studies on the Akt strain of MLV identified a
region downstream of the 5'ss that modulates splicing
efficiency. In the course of examining the contribution of
various sequence elements to viral RNA dimer initiation,
Aagaard et al. [69] noted that deletion of a stem loop
structure (DIS-1) immediately 3' of the 5'ss resulted in a
5–10 fold increase in the level of spliced RNA. Given its
close proximity to the 5'ss, the secondary structure of DIS-
1 may block base pairing of U1 snRNA to the 5' ss.
In summary, it would appear that retroviruses have used a
common set of tools (suboptimal 3'ss, splicing enhancers,
splicing silencers) to regulate the extent of viral RNA
processing and achieve a balanced level of unspliced and
spliced RNAs compatible with virus replication. The use of
cellular factors (SR proteins, hnRNP proteins) to regulate
splicing suggests that the extent of RNA processing and
hence, the capacity of the virus to replicate, is also dictated
by the required mix of host cell splicing regulatory factors
and determine the host range of the virus. Supporting this
conclusion are observations from studies using MLV and
HIV-1 based vectors. Lee et al. [70] noted that virus titers
from a MLV-based vector varied significantly between var-
ious cell lines and showed that at least part of the problem
resided in marked differences in viral RNA processing.
Since the vector used was constant, the variation seen is
likely due to different levels of host splicing factors. A sim-
ilar phenomenon may also partially explain the inability
of murine cells to support HIV-1 replication. Zheng et al.
[71] observed excessive splicing of HIV-1 RNA upon intro-
duction of provirus into murine cells. This problem could
be alleviated by expression of the human p32 protein,
which binds to and likely sequesters SF2/ASF. By reducing
the availability of SF2/ASF in this manner, the extent of
HIV-1 RNA splicing is reduced, permitting accumulation
of genomic RNA. These findings highlight the vulnerabil-
ity of retroviruses to modulation of host factor regulating
RNA processing and raise the possibility of therapeutic
intervention at this level.Retrovirology 2006, 3:18 http://www.retrovirology.com/content/3/1/18
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Polyadenylation
Polyadenylation plays a key role in the life of an mRNA,
regulating its transport, translation and turnover. Control-
ling where in the retroviral genome polyadenylation
occurs is critical for replication. For several retroviruses
(i.e. HTLV-1, HTLV-2, bovine leukemia virus, RSV, murine
leukemia virus), choice of polyadenylation site use is
straightforward since the major signal for the reaction
(AAUAAA) occurs only once in the transcript. For other
retroviruses (i.e. HIV-1, equine infectious anemia, Molo-
ney murine leukemia virus), the situation is rendered
more complex by the duplication of the polyadenylation
signals (AAUAAA and the 3' G/U-rich sequence) at the 5'
and 3' ends of the transcript. Successful replication has
necessitated that these viruses evolve mechanisms to sup-
press recognition of the first polyadenylation signals.
Although research has shown that sequences within U3
(present only at the 3' end of the retroviral RNA) can
enhance use of the downstream polyadenylation signal,
this finding does not readily explain its almost exclusive
use.
Regulating HIV-1 RNA polyadenylation
In the case of HIV-1, it was initially believed that the prox-
imity of the first polyadenylation site to the start site of
transcription reduced its recognition by the host polyade-
nylation machinery, possibly as a result of a secondary
structure that masks the AAUAAA polyadenylation signal
[72,73]. However, subsequent work has provided an alter-
native explanation. Inactivation of the first 5'ss (SD1) dra-
matically increased use of the promoter proximal
polyadenylation signal [74-76]. Subsequent experiments
determined that recruitment of U1 snRNP to SD1 acts to
suppress use of this polyadenylation site, possibly
through an interaction between the U1 70 K protein of U1
snRNP and components of the polyadenylation machin-
ery, in particular polyA polymerase [75,77].
In addition to the cis-acting signals that control use of the
first polyadenylation site, ESE3 and ESS3 play a role in
modulating use of the second polyadenylation signal.
Deletion of ESE3 not only results in decreased use of SA7
but also an inhibition of Rev-dependent viral gene expres-
sion [40,78] that correlated with loss of polyadenylation
of the incompletely spliced viral RNA [79]. Polyadenyla-
tion of viral RNA could be restored by the deletion of ESS3
and ESE3, indicating that these two elements not only
play antagonistic roles in the recognition of SA7 but also
in the 3' end processing of viral RNA [79].
Cellular and viral proteins have been implicated in regu-
lating HIV-1 RNA polyadenylation. Experiments with
Sam68, a member of the STAR family of RNA binding pro-
teins, revealed that its overexpression dramatically
enhanced Rev function [80-83], which correlated with the
ability to stimulate 3' end processing of incompletely
spliced viral RNA [79]. With the demonstration that
Sam68 is essential for both Rev-induced viral gene expres-
sion and HIV-1 replication, it would appear that it might
play a pivotal role in the processing of the incompletely
spliced viral RNAs that renders them competent for trans-
port to the cytoplasm and subsequent translation [84].
Interestingly, the virus itself also modulates the cell's poly-
adenylation machinery. Vpr-expressing viruses induce a
dephosphorylation of poly A polymerase, the enzyme
responsible for addition of the poly A tail following cleav-
age, an alteration that leads to increased activity [85].
While Vpr expression does lead to a modest increase in
viral RNA levels, this is not achieved through changes in
either viral RNA stability or poly A tail length. However, it
remains to be determined whether Vpr might affect the
initial processing of the viral transcripts in the nucleus.
HIV-1 Tat may also impact on viral RNA polyadenylation
through its ability to increase expression of the 73 kDa
component of the cleavage and polyadenylation specifi-
city factor (CPSF), a key factor in 3'end processing [86].
MLV: different virus, different solution
Although both HIV-1 and Moloney murine leukemia
(MoMLV) virus share the same problem of suppressing
use of the 5' proximal polyadenylation signal, they have
evolved different mechanisms to solve the problem. In
contrast to HIV-1, mutation of the 5'ss in MoMLV has lit-
tle effect on the use of the first polyadenylation signal.
Rather than regulating use of the signal, MoMLV appears
to have adopted the use of inefficient signals, resulting in
a significant proportion of viral transcripts failing to use
either of the two viral encoded polyadenylation signals
and the RNA terminates in the adjacent cellular sequences
[87].
RSV, the NRS, and 3'-end formation
In the avian RSV, the NRS appears to play an important
role in modulating polyadenylation efficiency. Avian ret-
roviral 3'-end formation is inherently inefficient with
~15% of RNA representing read-through transcripts where
poly(A) addition occurs at downstream cellular sites [88].
Miller and Stoltzfus [89] showed that deletions encom-
passing the NRS increased the level of read-through tran-
scripts and proposed that the deleted sequence(s) bind
factors that stabilize the poly(A) machinery to allow more
efficient polyadenylation. The NRS appears to be the rele-
vant element since specific mutations or deletions within
this region also result in 3'-end formation deficiencies
[8,90]. It was proposed that the stalled splicing complex
between the NRS and viral 3'ss serves the same function as
the splicing process [90]. This model is consistent with
observations that NRS mutations induce transcriptional
read-through and splicing into the cellular myb gene in
chickens, which results in short-latency lymphomas [91].Retrovirology 2006, 3:18 http://www.retrovirology.com/content/3/1/18
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It will be important in the future to determine the mecha-
nism by which the NRS boosts polyadenylation of
genomic RNA.
Nuclear export of incompletely spliced RNA
Once the challenges of manipulating the splicing appara-
tus to preserve pools of unspliced RNA have been met, ret-
roviruses face the task of exporting these molecules in a
cell that normally restricts unspliced RNA to the nucleus.
This could involve overcoming nuclear retention signals
and/or recruiting export factors that otherwise would have
little attraction for genome-length viral RNA. Export of
bulk mRNA is thought to be facilitated by the recruitment
of the general export factor TAP/NXF1:p15 to the RNA
through different adaptor proteins, including REF/Aly and
SR proteins [92]. Adaptor loading onto RNA occurs either
through an interaction with a mark deposited upon intron
removal, such the exon junction complex (EJC), or by
direct binding to elements within the RNA. How then do
unspliced retroviral RNAs, which don't benefit from the
deposition of an EJC, get efficiently exported? As with
splicing and polyadenylation, different viruses have
evolved distinct mechanisms to export unspliced RNA. In
the case of HTLV-1/2 and lentiviruses such as HIV-1, the
virus encodes an accessory protein that targets unspliced
RNA to an export pathway distinct from that used by most
cellular mRNA. In contrast, simple retroviruses like Mason
Pfizer monkey virus (MPMV) harbor cis-elements that
bind host cell export factors directly, independent of splic-
ing. Moreover, some of these proteins are multifunc-
tional, acting early in splicing regulation and later in RNA
trafficking and perhaps viral RNA encapsidation.
Control of HIV-1 RNA export out of the nucleus
Early mutagenesis studies of HIV-1 revealed that loss of
Rev expression resulted in a complete loss of viral struc-
tural protein expression without significantly affecting
levels of the various viral RNAs. Subsequent fractionation
studies determined that the absence of HIV-1 structural
protein production upon inactivation of the Rev reading
frame was due to sequestration of the unspliced 9 kb and
singly spliced 4 kb viral RNAs in the nucleus [93-96]. Only
the fully processed 2 kb viral mRNAs accumulate in the
cytoplasm in the absence of Rev. The basis for the nuclear
retention of the 9 kb and 4 kb HIV-1 RNAs remains poorly
understood, with some groups attributing it to partial
assembly of spliceosomes on the RNA [97], while others
have identified cis-acting repressive (CRS) or instability
(INS) sequences within the Gag, Pol and Env reading
frames that are able to confer Rev-dependency in heterol-
ogous contexts [98-107]. As these inhibitory sequences
are removed by splicing in the generation of the multiple
spliced, 2 kb RNAs, no impediment exists for the transport
of these viral RNAs via the general mRNA export pathway
of the cell. Additional mutations also demonstrated the
requirement of a 240 nt sequence (designated the Rev-
responsive element, RRE) within the env reading frame for
Rev function [95,96]. The RRE serves as a point of interac-
tion of viral RNA with the Rev protein.
Intense investigation of HIV-1 Rev function has resulted
in it being one of the most thoroughly characterized
export systems and readers are referred to more extensive
reviews on its function that are briefly summarized here
[95,96]. Multiple domains are required for Rev to func-
tion. Within the amino terminal portion of Rev is an
arginine-rich stretch between a.a. 35–50 that comprises a
nuclear/nucleolar localization signal (NLS/NoLS) and
forms an alpha helix able to bind in the major groove of
the primary Rev-binding site of RRE RNA. Within the car-
boxyl terminal portion is a leucine-rich sequence between
a.a. 73 and 84 that forms the nuclear export signal (NES).
Despite steady-state accumulation in the nucleolus, the
presence of both an NLS and NES within Rev results in the
protein constantly moving between the nucleus and cyto-
plasm. Nuclear import is mediated by binding of the
arginine-rich region to the transport mediator importin β
and nuclear export is achieved through binding of Crm1/
Exportin-1 to the leucine-rich NES of Rev in a Ran/GTP
dependent manner. This ternary complex (Rev/Crm1/
RanGTP) then interacts with the FG-repeats of nucleop-
orins and the complex moves through the nuclear pore.
Once within the cytoplasm, the RanGTP within the com-
plex is hydrolyzed to RanGDP by RanGAP and the ternary
complex disassembles.
Although it is possible that Rev interacts with all RRE-con-
taining HIV-1 RNAs in the nucleus (the 9 and 4 kb class of
RNAs), studies have indicated that several parameters dic-
tate which RNA will be exported to the cytoplasm. First
was the demonstration that Rev function was dependent
upon the continued transcription of the target RNA
despite the presence of significant levels of RRE-contain-
ing RNA in the nucleus [108]. This finding suggests that
Rev must act before the viral RNA either becomes fully
spliced or is committed to retention in the nucleus. Sec-
ond was the observation that Rev-induced export required
3' end processing of the RNA as only polyadenylated viral
RNAs are transported to the cytoplasm [79,109]. There-
fore, while Rev is able to bypass the cellular mechanisms
that prevent export of incompletely spliced RNAs from
nucleus, the affected RNAs must meet a limited set of cri-
teria (5' cap, 3' poly A tail) to be exported. The require-
ment for 3' end processing for Rev-mediated export may
provide a partial explanation for the need for continued
synthesis of the target RNA. Recent studies have estab-
lished that a tight coupling exists between the various
processing steps leading to mature mRNAs, suggesting
that once 3' end formation occurs it would stimulate the
removal of the upstream intron [110-112]. Therefore RevRetrovirology 2006, 3:18 http://www.retrovirology.com/content/3/1/18
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may need to act within the brief time frame between 3'
polyadenylation and subsequent splicing of the RNA to
induce export of the unspliced and partially spliced viral
RNAs. The population of incompletely spliced HIV-1
RNAs that fail to become polyadenylated are likely
retained in the nucleus and degraded.
Once the Rev/Crm-1/RanGTP complex assembles on the
appropriate RNA, its journey from the site of synthesis to
the cytoplasm begins. Most of the details of this process
remain unclear but recent experiments have begun to
identify host factors that play pivotal roles in the process.
At least two members of the DEAD box RNA helicase fam-
ily, DDX3 and DDX1, play essential roles in mediating
Rev-dependent RNA export [113,114]. Depletion of either
protein is associated with a marked reduction in Rev activ-
ity [113,114]. DDX1 also interacts with Rev via the N-ter-
minal domain, suggesting a role in initial complex
assembly [114]. For DDX3, its interaction with CRM-1
and localization to the outer nuclear membrane suggests
that it might act to facilitate the translocation of the Rev-
RNA complex through the nuclear pore [113]. Once on
the cytoplasmic face of the nuclear membrane, another
host factor, hRIP, appears to be required for release of the
viral RNA into the cytoplasm [115,116] as depletion of
the protein results in accumulation of viral RNA on the
cytoplasmic face of the nucleus. A similar perinuclear
accumulation of viral RNA is also observed upon overex-
pression of a C-terminal deletion mutant of Sam68, des-
ignated Sam68∆C [83]. However, in this instance
subsequent studies (Marsh and A.C., unpublished) indi-
cate that this factor acts at a later step in the cytoplasmic
metabolism of the viral RNA.
CTE pathway
Although the study of the HIV-1/lentivirus systems clearly
demonstrated a role for Rev-like proteins as adaptors to
facilitate the export of viral RNAs to the cytoplasm, paral-
lel work indicated that other viruses evolved alternative
solutions to the export problem. An element at the 3' end
of the MPMV designated the constitutive transport ele-
ment (CTE) was shown to support Rev-independent HIV
structural protein expression [117-119]. An element with
similar activity was found in simian retrovirus type I
[120]. The CTE is able to competitively inhibit cellular
mRNA export (unlike Rev or the RRE) and interacts with
the host export factor NXF1 [121-123]. Thus, in contrast
to HIV-1 where Rev serves as an adaptor to access the
export pathway, direct binding of NXF1 to the CTE
bypasses the requirement for a virally-encoded protein.
DR1/DR2 elements of avian retroviruses
Identification of the CTE export element in MPMV
implied that similar export elements would be found in
other simple retroviruses. One such element required for
cytoplasmic accumulation of Pr-C RSV unspliced RNA
was localized to the direct repeat region downstream of
the src gene (DR2) [124]. A second repeat (DR1) located
upstream of src shows similar activity, and at least one DR
is required for RSV replication. The DR sequence is con-
served between avian retroviruses and a similar activity
was ascribed to the DR element in RAV-2 ALV [125].
Despite the clear export activity of the DR elements in
reporter assays, unambiguous demonstration of an export
role in RSV is complicated by the finding that DR dele-
tions have effects apart from export, including destabiliza-
tion of unspliced RNA and defective particle assembly
[124,126,127]. While the DR elements harbor export
activity, they are not absolutely required for export since
the results from Simpson et al. [126] indicate that some
unspliced RNA is exported and translated even in their
absence.
As discussed above, HIV-1 Rev serves as an adaptor to tar-
get HIV RNA to the CRM1 export pathway, whereas the
MPMV CTE directly binds NXF1 for export via the mRNA
route. There is no obvious sequence similarity between
the MPMV CTE and the avian DR elements, but it is per-
haps reasonable to speculate that other simple retrovi-
ruses evolved to exploit the NXF1 pathway for export. Two
studies took advantage of reagents to block the CRM1
pathway and found that, like the MPMV CTE, export of
DR reporter RNAs was unaffected under conditions that
blocked Rev export [125,128]. Thus, the CRM1 pathway is
not required for ALV RNA export. Surprisingly, NXF1
binding to the ASV DR elements has yet to be demon-
strated, implying that avian retroviral unspliced RNA
export exploits yet a different pathway from HIV-1 and
MPMV. However, the possibility that the avian DR ele-
ments bind a cellular adaptor molecule that functions
similarly to NXF1, or that interacts with NXF1, has not
been eliminated.
The importance of the road traveled to the cytoplasm
It is well established that the nuclear history of an mRNA
can influence its fate in the cytoplasm. This property can
be attributed to the nature of the mRNP that assembles on
the RNA. One well-studied example is the affect that
mRNA splicing has on mRNP composition through the
deposition of the exon junction complex (EJC) and its
consequences to downstream events such as export, trans-
lation, and decay [129]. The possibility that cis elements
that direct retroviral RNAs to one export pathway or
another might influence downstream cytoplasmic events
was realized with the observation that unspliced RSV
RNAs that lack DRs produce readily detectable amounts of
Gag protein but are defective in particle assembly
[126,127]. These investigators hypothesized that either
the RNA export defect rendered Gag synthesis below a
threshold level required for assembly or more intrigu-Retrovirology 2006, 3:18 http://www.retrovirology.com/content/3/1/18
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ingly, that the DR contains an element distinct from that
responsible for CTE activity and directs RNA to a cytoplas-
mic location that is conducive to production of assembly-
competent Gag protein.
Mammalian cells are nonpermissive for ALV infection due
to defects in RNA processing, RNA export, Gag cleavage
and particle assembly [124,126,130,131]. These observa-
tions are similar to those reported for ∆DR viruses in avian
cells and suggest that the RNP exported in mammalian
cells fails to deliver genome-length RNA to a cytoplasmic
location where translated Gag can assemble particles.
[124,126]. This idea is supported by work demonstrating
that ALV particles can be formed in mammalian cells
when the RRE is provided in cis and Rev in trans, i.e.,
when RNA is exported via the CRM1 pathway [106]. This
result seems at odds with the lack of an effect of CRM1
inhibitors in avian cells, but it is possible that productive
export occurs by more than one pathway, as is true for
HIV-1 (see below).
A recent report by Swanson et al. demonstrated a similar
link between HIV-1 unspliced RNA export and Gag assem-
bly [132]. Gag protein can be produced in murine cells
but is not processed or assembled into virions, which is
one reason that murine cells are nonpermissive for HIV-1
replication. These investigators demonstrated that rerout-
ing unspliced RNA export from the Rev/RRE pathway to
the CTE pathway restored efficient virion production. This
correlated with a redistribution of Gag from diffuse cyto-
plasmic localization when RNA export was Rev/RRE-
dependent to plasma membrane association when the
CTE route was used. Particle assembly occurs in human
cells regardless of the export pathway used by the Gag
RNA. Thus, as with ALV, productive HIV-1 RNA export
may produce some type of RNP 'mark' that influences
cytoplasmic RNA localization and the ability of the
encoded protein to reach assembly sites. Part of this mark
could lie in the association of hnRNP proteins on the
unspliced RNAs at a particular step of the viral gene
expression phase. Bériault et al. showed that disruption of
hnRNP A2 binding to its cognate cis sequence (the hnRNP
A2 response element or A2RE) also affected the cellular
distribution of Gag and the auxiliary protein Vpr, but only
at a late step that coincided with a block in unspliced HIV-
1 RNA export from the nucleus [133]. It will be important
to determine the composition of the RNPs that are and are
not competent to direct productive Gag synthesis. This is
clearly an area that deserves more research as it likely rep-
resents an interface between nuclear events and the forma-
tion/function of possible intracellular transport granules.
Intracytoplasmic trafficking of retroviral RNA
Once delivered into the cytoplasm, two fates exist for the
unspliced, genomic viral RNA: translation to produce the
structural proteins and selection for encapsidation into
the forming virions. The majority of unspliced retroviral
RNA is not captured for encapsidation but serves other
roles in generating viral structural proteins and enzymes
or as a cofactor for assembly ([134-137] and reviewed in
[138]). However, genomic viral RNA that is translated in
the cytoplasm must transition in some fashion to sites of
virus assembly to become encapsidated. The first evidence
suggesting a specific location for genomic RNA selection
for encapsidation has recently come to light in work from
Andrew Lever's group. Using fluorescence resonance
energy transfer (FRET), they were able to monitor the
interaction of Gag with unspliced viral RNA. Unexpect-
edly, the unspliced HIV-1 RNA was found to be captured
by Gag at a site at or adjacent to the centriole, near the
nuclear membrane [139]. The signal was dependent upon
psi-containing viral RNA. This was an infrequent event,
consistent with earlier reports indicating that the vast
majority of the unspliced viral RNA is not selected for
encapsidation but translated or used as a cofactor for
assembly [140,141]. The centriole region has also been
identified as an assembly site for type D assembling retro-
viruses such as MPMV [142,143]. Image analysis reveals
translating polyribosomes and co-assembly of capsids in
this region but it remains unclear if assembly of retroviral
type C HIV-1 capsids are also initiated in this region. This
binding event could represent the first step in the forma-
tion of an RNP transport complex (see below) to sites of
capsid formation. FRET has also been used successfully to
identify cellular regions at which Gag-Gag homo-oli-
gomerization in membranes occurs during viral assembly
[144,145] and these types of techniques will help deci-
pher some of the molecular interactions during viral rep-
lication.
Deciphering the relationship between the centriole, Gag
capture and encapsidation into virions, and the process
that directs viral genomic RNA (and possibly other viral
mRNAs) to the sites of assembly remains a considerable
challenge requiring targeting signals in the viral RNA, viral
proteins, and/or a host cell targeting machinery [146].
While RNA can move intracellularly by a variety of mech-
anisms (Brownian motion, active transport) [147], clues
about this process for retroviruses were provided by pio-
neering RNA trafficking studies in which vesicular traffick-
ing pathways were shown to deliver viral components to
assembly sites. Part of this newly described retroviral RNA
trafficking pathway relies on the recruitment of genomic
RNA from a cytoplasmic pool onto vesicles.
Retroviral RNA trafficking on cellular vesicles in the 
cytoplasm
The movement of MLV RNA to sites of virion assembly
was investigated by monitoring MLV genomic RNA move-
ment in live cells using a bacteriophage MS2 tethering sys-Retrovirology 2006, 3:18 http://www.retrovirology.com/content/3/1/18
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tem. In this study [148], it was shown that genomic RNA
traffics on recycling endosomal vesicles. Time-lapse fluo-
rescence video microscopy showed a directed and linear
trafficking pathway that was dependent upon the integrity
of the microtubules [148]. Transport required the psi RNA
packaging signal within the affected RNA and an intact
NC domain in Gag, consistent with their demonstrated
requirements for viral RNA packaging. The vesicles were
comprised of both endosomal and lysosomal vesicles as
evidenced by co-trafficking of the labeled RNA on trans-
ferrin- and lysotracker-positive vesicles in cells. Results of
experiments in which monensin was used, a drug that pre-
vents acidification of endosomal and organellar compart-
ments, indicated that trafficking was achieved on vesicles
that likely emanate from a steady-state endosomal com-
partment and not rapidly recycling vesicles that contain
Rab11. Gag protein is recruited from late endosomal/lys-
osomal compartments to these endosomal membranes by
the viral glycoprotein, Env, demonstrating important con-
tributions of Env to this process. Not only could cellular
RNAs replace viral RNA on vesicles in their system when
psi was mutated, but some evidence suggests that the psi
RNA sequence that is comprised of four stem loops in
MLV, harbours an endosomal trafficking signal [149].
Other studies suggested a similar role for recycling mem-
brane compartments and the expression of Env in the
assembly of MPMV virus particles [143], although RNA
trafficking was not examined. Despite the classical differ-
ences in the assembly pathways used by the two viruses
(MLV is a type C virus for which capsid assembly and mor-
phogenesis occur at the plasma membrane while MPMV
capsids assemble intracellularly at the centriole [143]) the
similarities in intracellular trafficking pathways that rely
on recycling membrane compartments and the require-
ment for Env in the assembly of virus particles warrants
further investigation [143]. Our own results add to this
story with the demonstration that Env expression can dra-
matically alter the distribution of HIV-1 genomic RNA in
HeLa cells (K. Lévesque, M. Halvorsen & A.J.M., unpub-
lished). Basyuk and colleague's work supports earlier evi-
dence that several retroviral Gags interact with kinesin
motor proteins to enable trafficking along microtubules.
The significance of these observations is yet to be deci-
phered but might put Gag as the key component of these
trafficking complexes. Both Gag and RNA were visualized
on the outside of translocating vesicles in the absence of
MLV capsids, suggesting that part of this trafficking path-
way is preceded by the formation of a cytosolic RNP com-
plex [148]. While it in not known where the recruitment
of MLV Gag and RNA occur, some insight was provided by
the work of Poole's et al. in which HIV-1 RNA capture by
Gag was shown to occur at the centriole [139]. MPMV
RNA appears to be cotranslationally assembled in this cel-
lular region, suggesting that this may be a point where the
viral RNA transitions from a free RNP particle into a mem-
brane-bound complex en route to the plasma membrane.
It remains to be determined whether these relationships
hold true for all retroviruses.
The RNA trafficking granule takes shape
The directed movement of viral RNA within the cytoplasm
relies on its interaction with multiple host proteins gener-
ating an RNA transport granule (RTG). The concept of an
RTG derives from the studies in neuronal cells, which
have both specialized functions and extended morpholo-
gies [150-152]. RTGs were shown to contain translational
components such as transfer-RNA synthetases, EF1α,
ribosomal RNAs, and molecular motor proteins such as
dynein and kinesin [153] (Table 1). Although character-
ized in specialized neuronal cells, the RTG likely exists in
some form in most other cell types, such as in fibroblasts,
T cells and epithelial cells [154,155], but the morpholo-
gies of some cell types make it difficult to study RNA traf-
ficking events (e.g., T cells). The RTG is indeed assembled
in oligodendrocytes and each granule can contain multi-
ple copies of HIV-1 mRNAs [151].
Published reports provide ample evidence that compo-
nents of the RTG play roles in multiple steps of retroviral
replication including transcription, RNA splicing, nucleo-
cytoplasmic transport, translation as well as genomic RNA
encapsidation (see Table 1). The effect of these factors on
RNA transport within neuronal cells and the identified
roles for many of these proteins in retrovirus replication
highlight a potential functional relationship between the
RTG machinery and retroviral replication. Retroviruses
might co-opt components of this cellular machinery to
ensure both the correct trafficking and localization of the
retroviral RNA for presentation to the translation machin-
ery and at sites of viral assembly for encapsidation into
virions [146]. The proteins found in the RTG are pre-
sented in Table 1 and a subset are discussed below.
RNA helicases: RHA, DDX1 & DDX3
As described above, nuclear export of retroviral RNA
involves several cellular RNA helicases. Recent observa-
tions have identified roles for RNA helicase A (RHA) and
two DEAD-box proteins, DDX1 and DDX3 in the nuclear
export of retroviral RNAs [113,156-158]. The functions of
the latter proteins have been reviewed earlier [159] and
are described in a previous section of this review. These
RNA helicase proteins appear to act at different stages of
retroviral gene expression. RHA depletion by siRNA
decreases translation of HIV-1 gag-pol mRNA, perhaps by
disrupting the remodeling of RNA-RNA and RNA-protein
interactions that are required for usage of unspliced tran-
scripts by the translation apparatus (K. Boris-Lawrie,
unpublished results). The recent identification of these
proteins in RTGs in the cytoplasm [160], albeit in special-
ized neuronal cells, leads to the idea that they may repre-Retrovirology 2006, 3:18 http://www.retrovirology.com/content/3/1/18
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sent part of the "protein mark" that initially tags retroviral
RNAs in the nucleus and remains associated during
nuclear export and subsequent RTG assembly in the cyto-
plasm. These findings suggest a possible mechanism by
which the nuclear history of the retroviral RNA and the
associated proteins might dictate gene expression patterns
in the cytoplasm analogous to the role of the exon junc-
tion complex [161,162].
hnRNP A2
hnRNPs in general are believed to function at many post-
transcriptional levels (reviewed in [163]). Particular atten-
Table 1: Links between components of RNA trafficking granules and retroviral replication
RTG Component Cellular Function Link to Retroviral Replication 
Cycle
Virion-Incorporation Reference*
Actin Cytoskeletal component for cell 
structure; scaffold for 
intracellular trafficking
Acts with HIV-1 Rev to 
promote nucleo-cytoplasmic 
RNA Transport; Binds 
retroviral Gags
Yes [178–181]
DDX1, 3, 5 RNA Helicases involved in RNA 
splicing, nuclear RNA export, 
RNA translation)
Promotes genomic RNA 
Nucleocyto-plasmic export
?[ 1 1 3 ]
EF1α Translation elongation factor 
involved in RNA anchoring via 
the actin cytoskeleton and in 
RNA translation
Binds HIV-1 Gag and may 
inhibit Gag RNA translation to 
favour encapsidation
Yes [182]
eIF5A Translation initiation factor 
involved in RNA translation 
initiation




hnRNP A/B Family of pre-mRNA splicing 
factors involved in RNA Splicing, 
RNA nucleocytoplasmic export, 
RNA trafficking
Influences retroviral RNA pre-
mRNA splicing, RNA 
trafficking and gene expression
No [34, 64, 133, 151]
Hsp70 Heat shock protein serving as a 
protein chaperone following 
heat or cellular stress
Promotes viral assembly, binds 
HIV-1 Vpr and promotes pre-
integration complex nuclear 
nuclear import
Yes [184–187]
Kinesin-1** (KIF-5, KHC) Molecular motor protein 
involved in energy-dependent 
intracellular translocation
The kinesin, KIF-4, interacts 
with retro-viral Gag Proteins
? [168, 169]
Nucleolin RNA binding or chaperone 
protein with numerous nuclear 
functions: remodeling of 
chromatin structure, ribosomal 
DNA transcription, ribosomal 
RNA maturation, ribosome 
assembly and nucleocytoplasmic 
transport
Binds genomic RNA of MLV 
and HIV-1
Yes (MLV) [188, 189]
PABP1 Poly(A) tail binding protein 
involved in RNA translation and 
RNA stability
Binds HIV-1 instability (INS) 
RNA sequences
?[ 1 9 0 ]
PSF Pre-mRNA splicing factor 
associated to polypyrimidine 
tract binding protein; Co-
transcriptional RNA splicing
Interacts with HIV-1 cis-
repressor (CRS) or INS RNA 
sequences
?[ 1 9 1 ]
Pur1α DNA- and RNA-binding protein 
involved in transcription and 
RNA transport
Binds TAR/Tat and can 
transactivate the HIV-1 LTR
? [192–194]
RHA RNA Helicase involved in RNA 
splicing and nuclear RNA export
Nucleocytoplasmic export and 
translation of genomic RNA
? [156, 157] & K. Boris-
Lawrie, personal 
communication
Staufen1*** Double-stranded RNA-binding 
protein involved in RNA 
trafficking & metabolism




tRNA synthetases Enzyme catalyzing the synthesis 
of tRNAs for RNA translation
Binds retroviral Gag and is 
virion incorporated
Yes [195, 196]
* Proteins identified in the RTG reported in the following references: [160, 197]; ** related kinesin molecular motor protein; *** HIV-1 pr55Gag 
should be considered part of a putative HIV-1 RTG since it is found in the Staufen1 complex ([172] and M. Milev & A.J.M., unpublished).Retrovirology 2006, 3:18 http://www.retrovirology.com/content/3/1/18
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tion has been placed on their role in the retroviral RNA
processing and nuclear export [39,64,164,165]. Some of
the evidence that particular hnRNPs could play other -yet
related- roles in retroviral replication such as RNA traffick-
ing are outlined here. Two 21 nucleotide sequences in
HIV-1 RNA were shown to bear striking homology to the
myelin basic protein (MBP) A2RE located in the 3'
untranslated region of the corresponding mRNA. The
MBP A2RE is required for RNA trafficking to the extremity
of dendrites of murine oligodendrocytes [150,166].
Injected HIV-1 and HIV-2 RNAs are also efficiently traf-
ficked in these cells with requirements identical to those
described for MBP mRNA: an intact A2RE, hnRNP A2
expression, microtubules and kinesin ([151] & A.J.M, E.
Barbarese, É.A. Cohen, J. Carson, unpublished results). By
sequence comparison, similar cis-acting elements can also
be found in HTLV-1 and HIV-2 RNAs but only the ele-
ment in HIV-2 vpr RNA has been shown to be active in
RNA trafficking [151]. Subsequent studies using proviral
HIV-1 constructs confirmed these results and demon-
strated that hnRNP A2 association with A2RE is critical for
late viral gene expression and genomic RNA encapsida-
tion [133]. Kinesin motor proteins are critical for hnRNP
A2-mediated RNA trafficking in oligodendrocytes and
hnRNP A2 was recently shown to interact with microtu-
bule adaptor proteins [167] and is present in RNA trans-
port granules [160]. This observation provides a physical
link to the cytoskeleton on which organelles, vesicles, and
RTGs are transported. The interactions between retroviral
Gag proteins and the kinesin motor protein, KIF-4, also
suggest that large multi-protein complexes are translo-
cated on the microtubule-based cytoskeleton in virus-
expressing cells [168,169]. These examples provide evi-
dence that viral RNP translocation is dictated by the activ-
ities of a variety of viral and cellular proteins.
Staufen1
While many of the proteins within the RTG have func-
tions in several cellular compartments, Staufen1 works
mainly in the cytoplasm. Staufen1 represents a bona fide
RNA trafficking protein whose function is conserved from
lower to higher eukaryotes. It plays a critical role in the
localization of several mRNAs in Drosophila, likely via its
direct interaction with target RNAs or in the context of
RNP complexes [170,171]. Several lines of evidence
implicate Staufen1 in regulating retroviral genomic RNA
encapsidation. First, Staufen1 associates with precursor
Gag protein and not the mature Gag proteins, and prefer-
entially co-precipitates with the genomic viral RNA but
not spliced forms [172]. Second, Staufen1 is encapsidated
in virions in stoichiometry to the number of genomic
RNA molecules present. Its identification in other retrovi-
rus particles suggests that Staufen1 may have a more gen-
eral role in the selection of genomic RNA for retroviral
encapsidation. Third, Drosophia Staufen preferentially
binds RNA homodimers [173], the form viral genomic
RNA takes during virion morphogenesis and within retro-
virus particles [174]. Fourth, Staufen1 knockdown by
siRNA results in a dramatic decrease in infectivity and
virus production [172]. Fifth and more importantly, mod-
ulation of intracellular levels of Staufen1 directly impacts
on genomic RNA encapsidation [172,175]; L. Abra-
hamyan, J.-F. Clément & A.J.M., unpublished results).
These findings suggest that Staufen1 may tag the genomic
RNA for encapsidation in the cytoplasm and be concomi-
tantly recruited into virus particles. Its function in this
process needs to be unequivocally proven, however pub-
lished data suggest that a molecular switch could be at
play that promotes the selection of two copies of genomic
RNA per virion [172]. Likely, the activity of Staufen1 is but
one of several factors needed for the "genomic RNA selec-
tion" process. It will be important to evaluate how the
functions of this and other RNA trafficking proteins are
interrelated along the retroviral RNA targeting pathway
from the nucleus to progeny virions.
Conclusion
Several functional and physical links between the tran-
scription, RNA processing, nucleocytoplasmic and cyto-
plasmic transport machineries as well as the metabolic
machineries for RNA in the cytoplasm are made by RNA-
binding proteins, some of which mark the RNA before
their exit from the nucleus and modulate RNA fate in the
cytoplasm. The journey of retroviral RNA from the
nucleus to its ultimate destination in the capsid is likely to
be characterized by similar phenomena, yet up until now
the details of these events have been scant. Many details of
how the RNA processing machinery is manipulated to
produce the appropriate spectrum of mRNAs and to allow
genome-length RNA to escape splicing have been revealed
in the last few years and illuminated potential targets for
arresting virus replication. Recent work has already
exploited our understanding of retroviral RNA processing
to develop small molecule inhibitors of HIV-1 RNA splic-
ing [176]. Another critical step in replication is the nuclear
export of genome-length RNA and efforts are being made
towards gaining a better understanding of the processes
that remodel nuclear RNPs and determine the fates of
viral RNA within the cytoplasm. A number of factors with
roles in cytoplasmic RNA transport have been found asso-
ciated with retroviral mRNA. A more detailed understand-
ing of the formation and function of retroviral RNA
trafficking granules and their components may provide
new insights into targets for rationale drug design, an idea
that recently has met with some success [177].
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